MENU

New viral and non-viral platforms for T-cell engineering

Speaker
  • Director, R&D, Cell Biology/Transfection at Thermo Fisher Scientific
    Biography
      Xavier de Mollerat du Jeu, Ph.D. is a Director of R&D transfection group at Thermo Fisher Scientific, working on creating and improving new nucleic acids delivery for both research and therapeutic applications. Xavier identified new DNA delivery approaches for hard to transfect cell lines and primary/stem cells and he is the inventor of Lipofectamine® 3000. Xavier's team is also focusing on new delivery solutions for CRISPR delivery, new scalable lentiviral production systems, mechanical delivery approaches for primary T cells and in vivo delivery of RNAi/mRNA for research and therapeutic application. He studied molecular biology and plant physiology at the University of Montpellier II in France, and received his Ph.D. in human genetics in 2003 from Clemson University in South Carolina. His thesis work involved identifying the gene(s) responsible for Split Hand/Split Foot Malformation 3 (SHFM 3). His post-doctoral fellowship research was in the laboratory of Dr. Michael G. Rosenfeld at UCSD, where he studied the roles of microRNAs in pituitary gland development. He joined Thermo Fisher in 2005.

    Abstract

    Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:

    New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System

    • Platform development process using Design of Experiment (DOE) methodologies
    • High-throughput to large scale bioreactor protocols
    • Cost benefits of this system over current methods

    Novel gene editing tools for primary T cells

    • New potent gene editing tools to increase knock-in and knock-out efficiency
    • Addressing non-viral delivery barriers through protocol optimization

    Show Resources

    New viral and non-viral platforms for T-cell engineering


    Specialty

    Biotechnology

    Medicine

    Gene Editing

    Crispr-Cas9

    Cell Culture

    Cancer Research

    Stem Cell Technologies

    Neuroscience

    Gene Expression

    Developmental Biology

    Cell Signaling / Transduction

    Cancer Therapeutics

    Brain

    Assay Development

    Oncology

    Geography

    Asia50%

    North America33%

    Europe17%

    Registration Source

    Website Visitors100%

    Job Title

    Research Scientist40%

    Clinical Laboratory Scientist20%

    Marketing/Sales20%

    Lab Management20%

    Organization

    Clinical Laboratory17%

    Biotech Company17%

    Medical School17%

    Other17%


    Show Resources
    Show Resources
    Attendees
    • See more